FDA Must Maintain Oversight Role In PMI Development, Groups Urge
This article was originally published in The Pink Sheet Daily
Executive Summary
Advocates argue patient medication information documents could resemble advertising if FDA does not review and approve them before they are used, regardless of resources concerns.